UDP-galactopyranose mutase (UGM)

UDP-galactopyranose mutase (UGM) is a flavin-dependent enzyme that catalyzes the reversible conversion of UDP-galactopyranose (UDP-Galp) to UDP-galactofuranose (UDP-Galf). This reaction is a critical step in the biosynthesis of galactofuranose, a five-membered ring sugar that is an essential component of the cell walls and surface glycoconjugates of several major human pathogens, including Mycobacterium tuberculosis, Aspergillus fumigatus, and various Leishmania species (PubMed: 22403951, UniProt: P96242). Because galactofuranose is entirely absent in humans and other mammals, UGM represents a highly attractive target for the development of narrow-spectrum antimicrobial and antifungal agents with potentially low host toxicity (PubMed: 17559231). Inhibition of UGM disrupts the structural integrity of the pathogen's cell wall or envelope, leading to impaired growth, increased susceptibility to other drugs, or cell death. While no UGM inhibitors have yet reached clinical use, numerous small molecules, including substrate analogs and 2-aminothiazole derivatives, are being investigated in preclinical studies for their ability to arrest pathogen growth (PubMed: 25100564). The enzyme's unique catalytic mechanism, which involves a covalent flavin-sugar intermediate, provides a specific template for structure-based drug design and high-throughput screening efforts.

Other names

UDP-galactose mutaseglfUDP-galactofuranose mutase

Inhibition of UDP-galactopyranose mutase prevents the conversion of UDP-galactopyranose to UDP-galactofuranose, thereby blocking the synthesis of essential galactofuranose-containing glycoconjugates required for pathogen cell wall integrity and survival.